Table 2 Factors influencing 3rd line overall survival (multivariable Cox model)
From: Pancreatic adenocarcinoma third line systemic treatments: a retrospective cohort study
Characteristic | HRa | CI 95%a | p-value |
|---|---|---|---|
3rd line chemotherapy type | |||
1) Fluoropyrimidine-based | — | — | |
2) Gemcitabine combinations | 0.74 | 0.45, 1.21 | 0.2 |
3) Gemcitabine | 1.63 | 0.98, 2.69 | 0.058 |
4) Erlotinib - based | 2.38 | 1.30, 4.34 | 0.005 |
5) Other | 1.20 | 0.85, 1.68 | 0.3 |
1st and 2nd line chemotherapy sequence | |||
L1=Gem and L2=FU-based | — | — | |
L1=FU-based and L2=Gem combinations | 1.19 | 0.61, 2.32 | 0.6 |
L1=Gem combinations and L2 =FU-based | 0.96 | 0.45, 2.03 | >0.9 |
Other sequence | 1.06 | 0.59, 1.91 | 0.8 |
Age at diagnosis | |||
a) under 50 | — | — | |
b) 50 to 70 | 0.94 | 0.64, 1.39 | 0.8 |
c) 70 or more | 1.00 | 0.59, 1.70 | >0.9 |
Year of treatment | |||
Before 2016 | — | — | |
After 2016 | 1.04 | 0.77, 1.41 | 0.8 |
Reason for 1st line chemotherapy arrest | |||
Progression | — | — | |
Other | 0.58 | 0.34, 0.99 | 0.045 |
Toxicity | 0.27 | 0.08, 0.90 | 0.033 |
Reason for 2nd line chemotherapy arrest | |||
Progression | — | — | |
Other | 0.77 | 0.27, 2.21 | 0.6 |
Toxicity | 0.82 | 0.44, 1.53 | 0.5 |
Hepatic metastases at diagnosis | |||
No | — | — | |
Yes | 1.58 | 1.18, 2.12 | 0.002 |